- Home
- SBGI vs SEPN Comparison
SBGI vs SEPN Comparison
Compare SBGI & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBGI
- SEPN
- Stock Information
- Founded
- SBGI 1986
- SEPN 2022
- Country
- SBGI United States
- SEPN United States
- Employees
- SBGI N/A
- SEPN N/A
- Industry
- SBGI Broadcasting
- SEPN
- Sector
- SBGI Industrials
- SEPN
- Exchange
- SBGI Nasdaq
- SEPN NYSE
- Market Cap
- SBGI 1.1B
- SEPN 1.0B
- IPO Year
- SBGI 1995
- SEPN 2024
- Fundamental
- Price
- SBGI $17.29
- SEPN $22.00
- Analyst Decision
- SBGI Buy
- SEPN Strong Buy
- Analyst Count
- SBGI 5
- SEPN 4
- Target Price
- SBGI $20.10
- SEPN $43.67
- AVG Volume (30 Days)
- SBGI 338.2K
- SEPN 196.7K
- Earning Date
- SBGI 11-06-2024
- SEPN 11-20-2024
- Dividend Yield
- SBGI 5.78%
- SEPN N/A
- EPS Growth
- SBGI N/A
- SEPN N/A
- EPS
- SBGI N/A
- SEPN N/A
- Revenue
- SBGI $3,370,000,000.00
- SEPN $981,000.00
- Revenue This Year
- SBGI $15.76
- SEPN N/A
- Revenue Next Year
- SBGI N/A
- SEPN N/A
- P/E Ratio
- SBGI N/A
- SEPN N/A
- Revenue Growth
- SBGI 3.12
- SEPN N/A
- 52 Week Low
- SBGI $11.13
- SEPN $18.62
- 52 Week High
- SBGI $18.20
- SEPN $26.34
- Technical
- Relative Strength Index (RSI)
- SBGI 58.65
- SEPN N/A
- Support Level
- SBGI $15.66
- SEPN N/A
- Resistance Level
- SBGI $16.72
- SEPN N/A
- Average True Range (ATR)
- SBGI 0.88
- SEPN 0.00
- MACD
- SBGI 0.03
- SEPN 0.00
- Stochastic Oscillator
- SBGI 69.26
- SEPN 0.00
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their content to pay-TV distributors.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.